These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37725919)

  • 1. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials.
    Haller H; Bianchi S; McCafferty K; Arthur S; Quinn CM; Budden J; Weir MR
    Kidney360; 2022 Dec; 3(12):2019-2026. PubMed ID: 36591361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of a Bespoke Hyperkalaemia Clinic to Facilitate Prescribing of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction.
    Ali I; Green D; Kalra P; Kalra PA
    Cardiorenal Med; 2022; 12(5-6):196-204. PubMed ID: 36044877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patiromer: A Review in Hyperkalaemia.
    Kim ES; Deeks ED
    Clin Drug Investig; 2016 Aug; 36(8):687-94. PubMed ID: 27380495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial.
    Bakris GL; Woods SD; Alvarez PJ; Arthur SP; Kumar R
    Kidney Med; 2021; 3(3):360-367.e1. PubMed ID: 34136782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
    Pitt B; Bakris GL; Weir MR; Freeman MW; Lainscak M; Mayo MR; Garza D; Zawadzki R; Berman L; Bushinsky DA
    ESC Heart Fail; 2018 Aug; 5(4):592-602. PubMed ID: 29767459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
    Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
    Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial.
    Weir MR; Rossignol P; Pitt B; Lund LH; Coats AJS; Filippatos G; Perrin A; Waechter S; Budden J; Kosiborod M; Metra M; Boehm M; Ezekowitz JA; Bayes-Genis A; Mentz RJ; Ponikowski P; Senni M; Castro-Montes E; Nicolau JC; Parkhomenko A; Seferovic P; Cohen-Solal A; Anker SD; Butler J
    Am J Nephrol; 2024 Aug; ():1-18. PubMed ID: 39159624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
    Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
    PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
    An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
    Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
    Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.